PMA device
BAROSTIM NEO® System
Cvrx, Inc. · Stimulator, Carotid Sinus Nerve (DSR, Class III) · First FDA decision Aug 16, 2019, newest Jan 20, 2023Heart failureHigh blood pressure (hypertension)
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
4
Breakthrough-designated
Device trials
15
Naming "BAROSTIM NEO"
MAUDE reports
100
Brand "BAROSTIM NEO", since 2015
PubMed studies
26
Mentioning "BAROSTIM NEO"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing BAROSTIM NEO® System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 4 of 4 decisions filed under this name.
- BAROSTIM NEO® SystemPMA supplement
P180050-S008 · Decided Jan 20, 2023 · 28 days after receipt · Normal 180 Day Track No User Fee
Device type: Stimulator, carotid sinus nerve (DSR) · Cardiology
3 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Transcutaneous Electrical Nerve Stimulators (TENS) - RETIREDNational determinationOn the books280.13Updated Jun 7, 2024
- Electrical Nerve StimulatorsNational determinationOn the books160.7Updated Aug 17, 2023
- Phrenic Nerve StimulatorNational determinationOn the books160.19Updated Jun 12, 2020
- Transcutaneous Electrical Nerve Stimulators (TENS)Local determinationIn effectL33802CGS Administrators, LLCUpdated Dec 7, 2023
Clinical trials
Device studies on ClinicalTrials.gov that name "BAROSTIM NEO", any status and sponsor, newest update first.
- BAROSTIM NEO Hypertension Pivotal TrialPivotal-lookingCompleted
CVRx, Inc.Not on our public-company list
NCT01679132 · 10 participants · Start Apr 12, 2013 · Primary completion Jul 2025
Device: BAROSTIM NEO System and Medical Management · For: Uncontrolled Hypertension
Sites: Phoenix, Arizona; Los Angeles, California; Washington D.C., District of Columbia · 11 sites in all
14 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "BAROSTIM NEO", and for the whole product code for context.
This brand
100 reports: 1 malfunction, 97 injury, 2 death
Whole product code DSR
451 reports: 4 malfunction, 416 injury, 31 death
Newest reports for this brand
- Barostim NeoInjury
3007972010-2026-00108 · Received Sep 16, 2026 · Event dated Mar 1, 2024
Device type: Stimulator, Carotid Sinus Nerve (DSR)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Hematoma; Neck Pain
4 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "BAROSTIM NEO"[tiab]. The summary above synthesizes these.
- Electrical carotid baroreceptor stimulation.
Schmidli J, von Allmen RS, Mohaupt MG · Wien Med Wochenschr · 2014
- Implant-Mediated Therapy of Arterial Hypertension.
Gierthmuehlen M, Plachta DTT, Zentner J · Curr Hypertens Rep · 2020Review
- Baroreceptor Stimulation for Resistant Hypertension.
Yoruk A, Bisognano JD, Gassler JP · Am J Hypertens · 2016Review
- Old problem surfaces with new technology: Twiddler's syndrome in Barostim NEO.
Rao A, Rao L, Parekh A, et al. · J Cardiovasc Imaging · 2024
- Antiarrhythmic effects of baroreceptor activation therapy in chronic heart failure: a case report.
Wang D, Veltmann C, Bauersachs J, et al. · Eur Heart J Case Rep · 2023Case Reports
- Baroreflex activation therapy in patients with heart failure with reduced ejection fraction: a single-centre experience.
Blanco C, Madej T, Mangner N, et al. · ESC Heart Fail · 2023
- Baroreflex Amplification and Carotid Body Modulation for the Treatment of Resistant Hypertension.
Groenland EH, Spiering W · Curr Hypertens Rep · 2020Review
- The role of neuromodulation in heart failure with preserved ejection fraction.
Algheffari J, Salameh AR, Adil L, et al. · Curr Probl Cardiol · 2025Review
- The Year in Electrophysiology: Selected Highlights From 2020.
Kothari P, Poorsattar SP, Graul T, et al. · J Cardiothorac Vasc Anesth · 2021
- Baroreceptor stimulation for resistant hypertension: first implantation in France and literature review.
Courand PY, Feugier P, Workineh S, et al. · Arch Cardiovasc Dis · 2014Case Reports, Review
- Nonpharmacologic Treatment for Heart Failure: A Review of Implantable Carotid Baroreceptor Stimulators As a Therapeutic Option.
Malangu B, Lanier GM, Frishman WH · Cardiol Rev · 2021Review
Other devices of this type
Also filed under product code DSR.
- Barostim SystemCvrx, Inc. · PMA 2023
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.